With a career that encompasses legal experience in both Munich and New York, Dr Tim Reinhard combines skills as a commercial mediator with expertise in biotechnology and medtech.
Today, Tim heads up Osborne Clarke’s German life sciences and healthcare group, advising national and international pharmaceutical, biotech and medtech companies clients in IP-related issues and regulatory matters.
He also provides legal guidance in the process of product development, including the negotiation of clinical trial, licensing and R&D agreements. And while technology plays an ever-growing role in the sector, Tim advises his clients in all legal aspects connected with the provision of digital healthcare offerings, such as digital applications, telemedicine and online pharmacies. In Who’s Who Legal Germany 2023 – Data, he is praised for his advice on digital health offerings, including digital apps and online pharmacies. In Who's Who Legal Germany 2023 - Data, his excellent advice on digital health offerings, including digital apps and online pharmacies, is recognised.
Alongside his advisory services, he represents his life sciences clients in litigation, primarily in patent infringement and competition law proceedings, also focusing on employee invention law.
As a trained commercial mediator, Tim supports his clients in mediation proceedings and is regularly called upon as a commercial mediator in IP-related disputes in the life sciences and healthcare sector.
He studied in Würzburg and obtained a doctorate in the area of intellectual property law before qualifying as a lawyer in 1996. Prior to joining Osborne Clarke in 2005, Tim held roles with an international law firm in Munich and New York.
Likeminded
Osborne Clarke has advised the mental health start-up Likeminded on its merger with nilo.health. The merger creates the new market leader for corporate mental health applications in the DACH region. Read more.
Tobii Dynavox
Osborne Clarke advises Tobii Dynavox on its agreement to acquire Rehadapt Engineering. Read more here.
RS Group plc
Osborne Clarke advises RS Group plc on the EUR 365m acquisition of Distrelec B.V. Read more here.
Taxfix
Osborne Clarke advises Taxfix on acquisition of start-up Steuerbot, read more
Sylphar NV and KaroPharma AB
Osborne Clarke advises Sylphar NV and Karo Pharma AB on purchase of Satin Naturel, read more
OSF Digital
Osborne Clarke advises OSF Digital on the acquisition of netnomics, read more
Galileo Global Education Germany
Osborne Clarke advises Galileo on acquisition of AKAD University, read more
Keen Venture Partners
Osborne Clarke advises Keen Venture Partners on EUR 25 million investment in Lendis, read more
Highland Europe
Osborne Clarke advises Highland Europe on investment in SoSafe, read more
DoorDash
Osborne Clarke has advised DoorDash on USD 750 million Series B financing round of rapid delivery firm Flink SE, read more
MA Ventures
Osborne Clarke advises MA Ventures on investment in Lykon, read more
Signiant
Osborne Clarke advises Signiant on acquisition of Lesspain Software, read more
Providence Strategic Growth
Osborne Clarke advises Providence Strategic Growth on investment in Hornetsecurity, read more
Handelsbatt
Osborne Clarke named "Law Firm of the Year Germany 2020", read more
Cathay Innovation
Osborne Clarke advises Cathay Innovation on MEDWING’s 28 million financing round, read more
Redalpine
Osborne Clarke advises Redalpine on EUR 6 million financing round in lengoo, read more
CeleraOne
Osborne Clarke advises CeleraOne on sale to Axel Springer, read more
Earlybird
Osborne Clarke advises Earlybird on €4m investment in Bitwala, read more
Goodix Technology
Osborne Clarke advised Goodix Technology on acquisition of Commsolid, read more
TomTec
Advised TomTec on its takeover by Philips, read more
Insights
Telemedicine on the rise in Europe
The European telemedicine industry is on the rise as a result of recent legalisation of activities such as remote treatment...
CJEU clarifies conditions for obtaining SPC protection for medicinal products
Royalty Pharma: the CJEU's latest decision on Supplementary Protection Certificates addresses when medicinal products can be "protected by a basic...
What will Brexit mean for the Life Sciences sector – in a deal or a no deal scenario?
With less than four months until the UK officially leaves the EU, amid confidence votes and delayed votes in the...